HCFA (Health Care Financing Administration) agrees national cover for arthritis blood filter
This article was originally published in Clinica
Cypress Bioscience's blood filtering device has gained national coverage approval from the US Health Care Financing Administration (HCFA) for use in Medicare patients with severe rheumatoid arthritis who have failed to respond to anti-rheumatic drugs. This will boost the fortunes of the tiny company whose revenue is less than a $1 million a quarter.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.